Use financial incentives to end drug shortages; Bay State drugmakers are hiring;

> Lack of financial incentives trumps capacity constraints in ongoing generic cancer drug shortages. Story

> Gasp! Some Boston-area drugmakers plan to boost their workforces by 5 percent to 10 percent, but it's taking them a long time to fill open positions, says a federal report. Story

> CMO Lonza is investing $12 million to expand its biopharmaceutical development services platform in Singapore. Item

> Hovione and Particle Sciences are targeting poorly water soluble drugs in a collaboration to provide drug development services. Article

> SGS North America is now ISTA-certified for thermal testing on insulated shipping containers used for temperature-sensitive products. Release

> Unimpeded by the recent warning letter issued for its California manufacturing plant, Impax is planning a$52-million expansion of production capacity at its Taiwan facility. Item

> Biologics services provider Omnia has unveiled spraying drying services for drug stabilization. Omnia release

> SAFC and Pfenex have teamed to produce therapeutic proteins and vaccine components. Story

Suggested Articles

The FDA has found issues with the testing practices of a U.S. generics maker that had specific problems with ADHD and weight-loss drugs.

A warning letter says Chinese API maker Yibin Lihao Bio-technical was found lying to the FDA about manufacturing unapproved heparin.

It took four tries over four years, but Perrigo has finally gotten FDA approval of its generic of Teva’s tricky-to-make ProAir HFA asthma inhaler.